PL1853232T3 - Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania - Google Patents
Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowaniaInfo
- Publication number
- PL1853232T3 PL1853232T3 PL06708346T PL06708346T PL1853232T3 PL 1853232 T3 PL1853232 T3 PL 1853232T3 PL 06708346 T PL06708346 T PL 06708346T PL 06708346 T PL06708346 T PL 06708346T PL 1853232 T3 PL1853232 T3 PL 1853232T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- dosage forms
- adn
- crystalline form
- stable crystalline
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65414905P | 2005-02-18 | 2005-02-18 | |
| PCT/EP2006/060055 WO2006087369A1 (en) | 2005-02-18 | 2006-02-17 | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them |
| EP06708346A EP1853232B1 (en) | 2005-02-18 | 2006-02-17 | Stable crystalline form of bifeprunox mesylate, dosage forms thereof adn methods for using them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1853232T3 true PL1853232T3 (pl) | 2010-01-29 |
Family
ID=36383746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06708346T PL1853232T3 (pl) | 2005-02-18 | 2006-02-17 | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7423040B2 (pl) |
| EP (1) | EP1853232B1 (pl) |
| AT (1) | ATE439831T1 (pl) |
| CA (1) | CA2598407A1 (pl) |
| DE (1) | DE602006008583D1 (pl) |
| DK (1) | DK1853232T3 (pl) |
| ES (1) | ES2331487T3 (pl) |
| HR (1) | HRP20090569T1 (pl) |
| PL (1) | PL1853232T3 (pl) |
| PT (1) | PT1853232E (pl) |
| SI (1) | SI1853232T1 (pl) |
| WO (1) | WO2006087369A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7964604B2 (en) * | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| US20080132520A1 (en) * | 2006-08-31 | 2008-06-05 | Winsemius Antje A | Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds |
| WO2008025781A1 (en) * | 2006-08-31 | 2008-03-06 | Solvay Pharmaceuticals B.V. | Bifeprunox doses for treating schizophrenia |
| US20090068290A1 (en) * | 2006-08-31 | 2009-03-12 | Michel Bourin | Bifeprunox doses for treating schizophrenia |
| US20100119622A1 (en) * | 2008-09-15 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE81975T1 (de) | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
| US6225312B1 (en) | 1996-03-29 | 2001-05-01 | Duphar International Research B.V. | Piperazine and piperidine compounds |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| CA2310950C (en) | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| AR045362A1 (es) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| EP1797871B1 (en) | 2004-09-21 | 2015-02-25 | Shandong Luye Pharmaceutical Co., Ltd. | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| AU2006283882B2 (en) | 2005-08-22 | 2011-06-23 | Solvay Pharmaceuticals B.V. | N-oxides as prodrugs of piperazine and piperidine derivatives |
-
2006
- 2006-02-16 US US11/354,652 patent/US7423040B2/en not_active Expired - Fee Related
- 2006-02-17 DK DK06708346T patent/DK1853232T3/da active
- 2006-02-17 AT AT06708346T patent/ATE439831T1/de active
- 2006-02-17 HR HR20090569T patent/HRP20090569T1/hr unknown
- 2006-02-17 ES ES06708346T patent/ES2331487T3/es active Active
- 2006-02-17 CA CA002598407A patent/CA2598407A1/en not_active Abandoned
- 2006-02-17 EP EP06708346A patent/EP1853232B1/en active Active
- 2006-02-17 PT PT06708346T patent/PT1853232E/pt unknown
- 2006-02-17 WO PCT/EP2006/060055 patent/WO2006087369A1/en not_active Ceased
- 2006-02-17 SI SI200630444T patent/SI1853232T1/sl unknown
- 2006-02-17 DE DE602006008583T patent/DE602006008583D1/de active Active
- 2006-02-17 PL PL06708346T patent/PL1853232T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2331487T3 (es) | 2010-01-05 |
| US20060194812A1 (en) | 2006-08-31 |
| EP1853232A1 (en) | 2007-11-14 |
| DE602006008583D1 (de) | 2009-10-01 |
| EP1853232B1 (en) | 2009-08-19 |
| WO2006087369A1 (en) | 2006-08-24 |
| HRP20090569T1 (hr) | 2009-11-30 |
| CA2598407A1 (en) | 2006-08-24 |
| US7423040B2 (en) | 2008-09-09 |
| ATE439831T1 (de) | 2009-09-15 |
| PT1853232E (pt) | 2009-11-12 |
| SI1853232T1 (sl) | 2010-01-29 |
| DK1853232T3 (da) | 2009-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
| TW200734327A (en) | Aminopyrimidines useful as kinase inhibitors | |
| MX2009009592A (es) | Aminopiridinas utiles como inhibidores de proteinas cinasas. | |
| MX2009010037A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| TNSN08140A1 (pl) | ||
| ZA200906264B (en) | Aminopyrimidines useful as inhibitors of protein kinases | |
| MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| ZA200705115B (en) | Indazole-carboxamide compounds | |
| TW200638934A (en) | Heteroaryl compounds as P2Y1 receptor inhibitors | |
| MX2009011811A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| GB0420831D0 (en) | Novel compounds | |
| PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
| TW200716204A (en) | Pharmaceutical composition | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. |